Literature DB >> 31670080

Single cell derived spheres of umbilical cord mesenchymal stem cells enhance cell stemness properties, survival ability and therapeutic potential on liver failure.

Yong Qiao1, Zhongjuan Xu2, Yanzhen Yu2, Shulan Hou3, Junsa Geng2, Tongqian Xiao4, Yu Liang5, Qun Dong6, Yan Mei7, Bin Wang8, Hong Qiao9, Jianwu Dai10, Guangli Suo11.   

Abstract

Umbilical cord mesenchymal stem cells (UCMSCs) have shown great potentials in regenerative medicine for their extensive sources, multilineage differentiation potential, low immunogenicity and self-renewal ability. However, the clinical application of UCMSCs still confronts many challenges including the requirement of large quantity of cells, low survival ability in vivo and the loss of main original characteristics due to two-dimensional (2D) culture. The traditional three-dimensional (3D)-spheroid culture can mimic in vivo conditions, but still has limitations in clinical application due to large size of spheroid against direct injection and inner cell death. Based on self-renewal tenet, we produced single cell derived sphere (SCDS) of UCMSCs through combining single cell pattern on chip with 3D culture. Compared with the 2D and traditional 3D culture, SCDS culture has many advantages to meet clinical requirements, including small size, higher abilities of survival and migration, and stronger hypoxia resistance and stemness maintenance. Furthermore, SCDS culture promotes angiogenesis in UCMSCs-xenografts and displays greater therapeutic potential on acute liver failure (ALF) in vivo. Our results suggest that SCDS culture may serve as a simple and effective strategy for UCMSCs optimization to meet clinical demand.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute liver failure; Single cell chip; Single cell derived sphere; Therapeutic potential; Umbilical cord mesenchymal stem cell

Mesh:

Year:  2019        PMID: 31670080     DOI: 10.1016/j.biomaterials.2019.119573

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  6 in total

1.  Extracellular magnetic labeling of biomimetic hydrogel-induced human mesenchymal stem cell spheroids with ferumoxytol for MRI tracking.

Authors:  Sen Yan; Ke Hu; Miao Zhang; Jingyi Sheng; Xueqin Xu; Shijia Tang; Yan Li; Sheng Yang; Guangxiang Si; Yu Mao; Yi Zhang; Feimin Zhang; Ning Gu
Journal:  Bioact Mater       Date:  2022-05-01

2.  Therapeutic efficiency of bone marrow-derived mesenchymal stem cells for liver fibrosis: A systematic review of in vivo studies.

Authors:  Zaid Al-Dhamin; Ling-Di Liu; Dong-Dong Li; Si-Yu Zhang; Shi-Ming Dong; Yue-Min Nan
Journal:  World J Gastroenterol       Date:  2020-12-21       Impact factor: 5.742

3.  The Extracellular Matrix Enriched With Exosomes for the Treatment on Pulmonary Fibrosis in Mice.

Authors:  Yanzhen Yu; Xingzhi Liu; Zhe Zhao; Zhongjuan Xu; Yong Qiao; Yuanshuai Zhou; Hong Qiao; Junjie Zhong; Jianwu Dai; Guangli Suo
Journal:  Front Pharmacol       Date:  2021-12-06       Impact factor: 5.810

Review 4.  Advance of Mesenchymal Stem Cells in Chronic End-Stage Liver Disease Control.

Authors:  Yun Gao; Xiushan Yin; Xiaomeng Ren
Journal:  Stem Cells Int       Date:  2022-10-07       Impact factor: 5.131

Review 5.  Xenogeneic stem cell transplantation: Research progress and clinical prospects.

Authors:  Lin-Li Jiang; Hui Li; Lei Liu
Journal:  World J Clin Cases       Date:  2021-06-06       Impact factor: 1.337

6.  Enhanced therapeutic effects of umbilical cord mesenchymal stem cells after prolonged treatment for HBV-related liver failure and liver cirrhosis.

Authors:  Yifan Jia; Xin Shu; Xiaoan Yang; Haixia Sun; Huijuan Cao; Hong Cao; Ka Zhang; Qihuan Xu; Gang Li; Yang Yang
Journal:  Stem Cell Res Ther       Date:  2020-07-10       Impact factor: 6.832

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.